Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03903640 · ClinicalTrials.gov registry record · Phase 2
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03903640 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants.
The verdict
NCT03903640, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overall survival.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DEVICE Optune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2021-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03903640
The ClinicalTrials.gov registry entry for NCT03903640 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03903640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03903640 about?
NCT03903640 is a clinical study titled "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis". This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overa...
What is the current status of trial NCT03903640?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-10-14. Estimated completion is 2021-11-03.
What interventions are being tested in trial NCT03903640?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Optune (DEVICE).
Who is sponsoring clinical trial NCT03903640?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.